| Verifiedfields | changed |
|---|---|
| Watchedfields | changed |
| Verifiedrevid | 406050182 |
| Iupac name | 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile |
| Width | 200px |
| Tradename | Afema |
| Legal status | Rx-only |
| Routes of administration | By mouth |
| Class | Aromatase inhibitor; Antiestrogen |
| Cas number | 102676-47-1 |
| Cas number 2 | 102676-31-3 |
| Atc prefix | None |
| Pubchem | 59693 |
| Chemspiderid | 53850 |
| Stdinchi | 1S/C14H13N3/c15-8-11-4-6-12(7-5-11)14-3-1-2-13-9-16-10-17(13)14/h4-7,9-10,14H,1-3H2 |
| Stdinchikey | CLPFFLWZZBQMAO-UHFFFAOYSA-N |
| Unii | H3988M64PU |
| Unii 2 | H0Q44H4ECQ |
| Index2 label | hydrochloride |
| Kegg | D02451 |
| Chembl | 9298 |
| C | 14 |
| H | 13 |
| N | 3 |
| Smiles | C1CC(N2C=NC=C2C1)C3=CC=C(C=C3)C#N |
Fadrozole (INN), sold under the brand name Afema (by Novartis), is a selective, nonsteroidal aromatase inhibitor which is or has been used in Japan for the treatment of breast cancer.[1][2]
References
- ^ Browne LJ, Gude C, Rodriguez H, Steele RE, Bhatnager A (February 1991). "Fadrozole hydrochloride: a potent, selective, nonsteroidal inhibitor of aromatase for the treatment of estrogen-dependent disease". J. Med. Chem.. 34 (2): 725–36. doi:10.1021/jm00106a038. PMID 1825337
- ^ Raats JI, Falkson G, Falkson HC (January 1992). "A study of fadrozole, a new aromatase inhibitor, in postmenopausal women with advanced metastatic breast cancer". J. Clin. Oncol.. 10 (1): 111–6. doi:10.1200/jco.1992.10.1.111. PMID 1530798. Archived from the original on April 15, 2013.